Stop Treating Symptoms. Start Engineering the Joint.
Arkion Biosciences is developing the world’s first synergistic, Trans-Osteochondral Chemotactic Gradient to halt catabolic destruction and drive true anatomic regeneration in Stage 3 and 4 Osteoarthritis.
THE PROBLEM:
The Failure of Single-Compartment Therapy
Osteoarthritis is not just a cartilage defect; it is a whole-joint physical and biochemical failure. Current treatments—such as intra-articular corticosteroids, generic Hyaluronic Acid (HA), or systemic enzyme inhibitors—fail because they target isolated symptoms and succumb to the joint's natural "Washout Effect."
They attempt to mask pain in the articular space while ignoring the dying, ischemic subchondral bone directly beneath it. Furthermore, generic intra-articular drugs are rapidly destroyed by endogenous enzymes or cleared via lymphatic drainage within days.
To achieve true Disease-Modifying Osteoarthritis Drug (DMOAD) status, we must stop viewing the joint as separate pieces and start treating it as a unified, interconnected biomechanical system.
THE ARKION PLATFORM:
The "Push-Pull" Regenerative Axis
Arkion Biosciences has engineered a proprietary, dual-action therapeutic platform that physically bridges the osteochondral junction. By establishing an indivisible biological axis between the subchondral bone and the articular cartilage, our platform forces the joint to repair itself from the inside out.
The Source (The "Push"): A targeted, highly-bioavailable oral polyanion that perfuses the ischemic subchondral bone marrow, restoring local vasculature and actively mobilizing resting endogenous Mesenchymal Stem Cells (MSCs).
The Target (The "Pull"): A localized, intra-articular biomimetic hydrogel that halts catabolic destruction and provides an enzyme-resistant physical scaffold, actively drawing those mobilized MSCs across the bone plate to execute full-thickness chondrogenesis.
The Pipeline
ARK-02 (Oral Component)
The "Trojan Horse" Lymphatic Prodrug
ARK-02 solves the historic impossibility of delivering massive, highly-charged polyanionic drugs (Pentosan Polysulfate) orally.
Steric Masking: We utilize a patented C8-C14 arylalkyl shielding moiety that creates a massive "rotational swept exclusion volume," physically bouncing destructive gut enzymes away from the fragile therapeutic backbone.
Lymphatic Routing: Encapsulated in a targeted enteric vehicle, ARK-02 acts as a biochemical grappling hook, forcing the drug into intestinal chylomicrons. This forces the drug into the lymphatic system, flawlessly bypassing first-pass liver destruction and safely delivering the active polyanion to the subchondral bone marrow.
ARK-C001 (Intra-Articular Component)
The Disease-Modifying Viscoelastic Scaffold
ARK-C001 is a fundamentally new class of macromolecular engineering. We have covalently tethered a highly sulfated MMP-13 inhibitor to a high-molecular-weight Hyaluronic Acid backbone utilizing a mathematically restricted, 16-Ångström spatial spacer.
The Trap: The precise spatial extension isolates the therapeutic payload, allowing it to physically insert into and irreversibly jam the active site of catabolic MMP-13 enzymes.
The Umbrella: Simultaneously, the spacer pulls the massive HA backbone directly over the active site, creating a severe steric shield that physically blocks endogenous hyaluronidase from destroying the drug.
The Result: A shear-thinning, non-Newtonian joint cushion that provides unprecedented residency time and acts as a pristine CD44-binding scaffold for cellular repair.
THE COMMERCIAL MOAT
Engineered for Maximum Regulatory Exclusivity
Arkion Biosciences is not just engineering molecules; we are engineering unassailable commercial assets. ARK-C001 and ARK-02 are legally and physically designated as a singular, co-packaged FDA Combination Product Kit.
By unifying the oral blister pack and the terminally sterilized pre-filled hydrogel syringe under a single unified prescribing label, we establish an indivisible article of commerce. This structural framework guarantees New Chemical Entity (NCE) exclusivity across the entire combination platform while physically and legally preempting off-label generic substitution at the pharmacy level.
Leadership and Investor Relations
Dr. Richard Molock
Founder and Inventor
Dr. Richard Molock is the architect of the Arkion Protocol and a pioneer in the biophysics of macromolecular joint retention and osteochondral restoration. With an extensive background in Pharmacy and advanced therapeutic formulation, Dr. Molock founded Arkion Biosciences to eliminate the mechanical and biochemical failure modes that have plagued osteoarthritis treatment for decades.